1. Safety of Sotrovimab use in children with COVID-19: an Italian experience.
- Author
-
Venturini E, Fusani L, Lo Vecchio A, Scarano SM, Garazzino S, Pruccoli G, Donà D, Lancella L, Castelli Gattinara G, and Galli L
- Subjects
- Adolescent, Adult, Humans, Child, Retrospective Studies, Antibodies, Monoclonal, Humanized, Italy, COVID-19, Antibodies, Neutralizing
- Abstract
Sotrovimab is a monoclonal antibody approved in adult and adolescents at high risk for COVID-19. Thirty-three children evaluated in five Italian paediatric centres received Sotrovimab infusion and were retrospectively enrolled from December 2021 to April 2022. In more than half of cases (19/33, 57.6%) Sotrovimab was prescribed off-label. Overall, the infusion was well tolerated with no significative differences in those receiving an off-label prescription. All children had a complete recovery. Data on the safety of Sotrovimab should be investigated in a larger paediatric cohort, considering the continuous selection of new SARS CoV-2 variants which may be more or less susceptible to the effects of the Sotrovimab.
- Published
- 2024
- Full Text
- View/download PDF